Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying
Cycle design and robustness testing using advanced process analytical technology.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 88-93

Conclusion

The study indicates that safety margins for shelf temperature and chamber pressure for a given product can be pre-evaluated in a laboratory using advanced PAT tools and therefore may allow for a rational QbD approach in the future. In addition, product resistance data obtained from MTM may provide valuable information about microcollapse in the product ("benchmark" properties). This information can be very useful in interpreting the effect of temperature or pressure deviations on a product.

Henning Gieseler, PhD,* and Stefan Schneid work in the Division of Pharmaceutics at the University of Erlangen, Erlangen, Germany 91058, tel. +49 9131 85 29545,
Tony Kramer works at the Ecolab Research Center in Eagan, Michigan.

*To whom all correspondence should be addressed. Submitted: Jan. 23, 2008. Accepted. Apr. 23, 2008.




What would you do differently? Email your thoughts about this paper to
and we may post them to the site.

References

1. J. Wechsler, "Modernizing Pharmaceutical Manufacturing," Pharm. Technol. 26 (2002).

2. FDA/ORA, "Compliance Policy Guide, Sub Chapter 490.100," Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval (CPG 7132c.08).

3. M.J. Pikal and H.R. Costatino, "Lyophilization of Biopharmaceuticals" in Biotechnology: Pharmaceutical Aspects, R.T. Borchard and C. R. Middaught, Eds. (AAPS Press, Arlington, VA, Vol. II, 2004).

4. X. Tang, S.L. Nail, and M.J. Pikal, "Freeze-Drying Process Design by Manometric Temperature Measurement: Design of a Smart Freeze-Dryer," Pharm. Res. 22 (4) 685–700 (2005).

5. H. Gieseler H, T. Kramer, and M.J. Pikal, "Use of Manometric Temperature Measurement (MTM) and SMART Freeze Dryer Technology for Development of an Optimized Freeze-Drying Cycle," J. Pharm. Sci. 96 (12), 3402–3418 (2007).

6. H. Gieseler, "Process Analytical Technology for Freeze-Drying: Cycle Optimization in the Laboratory," Eur. Pharm. Rev., 1, 2007.

7. F. Fonseca et al., "Collapse Temperature of Freeze-Dried Lactobacillus bulgaricus Suspensions and Protective Media," Biotechnol. Prog. 20, 229-238 (2004).

8. E. Meister and H. Gieseler, "Evaluation of Collapse Temperatures by Freeze-Dry Microscopy: Impact of Excipient Concentration on Measured Transition and the Overall Dependence on Measurement Methodology," in Proceedings of Fifth World Meeting on Pharmaceutics and Pharmaceutical Technology (Geneva, Switzerland, March 2006).

9. S. Rambhatla et al., "Cake Shrinkage During Freeze Drying: A Combined Experimental and Theoretical Study," Pharm. Dev. Technol, 1, 33–40 (2005).

10. S. Tchessalov, "Principles of Lyophilization Cycle Scale Up" in Processing CPPR Freeze Drying of Pharmaceuticals and Biologicals Conference (Garmisch-Patenkirchen, October 2006).

11. M.J. Pikal, "Use of Laboratory Data in Freeze Drying Process Design: Heat and Mass Transfer Coefficients and the Computer Simulation of Freeze Drying," J. Parent. Sci. Technol. 39 (3), 115–138 (1985).

12. J.P Dolan, "Use of Volumetric Heating to Improve Heat Transfer During Vial Freeze Drying" in Mechanical Engineering (PhD Thesis, Virginia Polytechnic Institute, Blacksburg, VA, 1998).

13. M.J. Pikal and S. Shah, "The Collapse Temperature in Freeze Drying: Dependence on Measurement Methodology and Rate of Water Removal from the Glassy Phase," Int. J. Pharm. 62, 165–186 (1990).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here